Developability of Biopharmaceuticals
Tuesday, December 4 – Thursday, December 6 2012
Location: Boston, MA
Integrating developability early in biopharmaceutical development to reduce time and costly drug attrition
Ask yourself this; what would a perfect developability assessment, earlier in the drug development process, mean to you?
Some of the leading drug developers are already carrying out an optimized developability assessment and are mitigating many of the challenges faced in later stages of development. Poor expression, misfolding or aggregation can cause significant delays in moving molecules forward into the manufacturing stage of development. These problems are frequently avoidable for the sake of relatively little investment early in the drug development process.
Developability of Biopharmaceuticals has been designed to support drug developers in reducing the cost, risk and time of development. The agenda focuses on engineering developability in early drug development to ‘design in’ desirable manufacturing properties, together with addressing safety and efficacy in early drug development to minimize costly attrition..
**MassBio members are eligible for a 10% discount off the registration fee. Simply quote ‘MASSBIO’ when registering.**